公开(公告)号：EP1827492B1

公开(公告)日：2010-08-11

申请号：EP05852645.0

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： RASTELLI, Luca ,  POLLACK, Vincent, A. ,  TSE, Kam, Fai ,  KLAKAMP, Scott ,  FOORD, Orit ,  LIANG, Meina ,  JIA, Xiao-Chi ,  XIAO, Feng ,  LICHENSTEN, Henri ,  HERRMANN, John ,  LAROCHELLE, William, J. ,  JEFFERS, Michael, E. ,  CHAPOVAL, Andrei ,  MEZES, Peter ,  ARA, Gulshan ,  TORGOV, Michael ,  KARKARIA, Cyrus ,  DAVAGNINO, Juan

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

公开(公告)号：EP1578799A2

公开(公告)日：2005-09-28

申请号：EP03796574.6

申请日：2003-12-02

申请人： Abgenix, Inc.

发明人： BABCOOK, John, S. ,  KANG, Jaspal, S. ,  FOORD, Orit ,  GREEN, Larry ,  FENG, Xiao ,  KLAKAMP, Scott ,  HAAK-FRENDSCHO, Mary ,  RATHANASWAMI, Palaniswami ,  PIGOTT, Craig ,  LIANG, Meina, L. ,  LEE, Rozanne ,  MANCHULENCHO, Kathy ,  FAGGIONI, Raffaella ,  SENALDI, Giorgio ,  QIAOJUAN, Jane, Su

IPC分类号： C07K16/00 ,  A61K39/395

CPC分类号： C07K16/241 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

摘要： Antibodies directed to the antigen TNFa and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFa. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

公开(公告)号：EP1827492A2

公开(公告)日：2007-09-05

申请号：EP05852645.0

申请日：2005-11-30

申请人： Curagen Corporation ,  Abgenix, Inc.

发明人： RASTELLI, Luca ,  POLLACK, Vincent, A. ,  TSE, Kam, Fai ,  KLAKAMP, Scott ,  FOORD, Orit ,  LIANG, Meina ,  JIA, Xiao-Chi ,  XIAO, Feng ,  LICHENSTEN, Henri ,  HERRMANN, John ,  LAROCHELLE, William, J. ,  JEFFERS, Michael, E. ,  CHAPOVAL, Andrei ,  MEZES, Peter ,  ARA, Gulshan ,  TORGOV, Michael ,  KARKARIA, Cyrus ,  DAVAGNINO, Juan

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human lonoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. the present invention futher provides bispecific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.